Collaborations & Alliances

HUTCHMED Earns $15M AstraZeneca Milestone

Initiates start-up activities for a global Phase III study of ORPATHYS in lung cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

HUTCHMED has received a $15 million milestone payment from AstraZeneca triggered by the initiation of start-up activities for SAFFRON, the first global Phase III study for ORPATHYS in combination with TAGRISSO in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition receptor (MET) driven tumors following progression after TAGRISSO.    SAFFRON is expected to begin enrolling patients in mid-2022 and follows importan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters